Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.

Por Backstrom, J. T., Hinkle, R. L., Flicker, M. R.
Publicado em 1997

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

Por Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, Germing, U
Publicado em 2013

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

Por Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Publicado em 2008

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an...

Por Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Publicado em 2008